Mode
Text Size
Log in / Sign up

Suprascapular Nerve Block Added to Steroid Injection Shows Early Pain Benefit in Adhesive Capsulitis

Suprascapular Nerve Block Added to Steroid Injection Shows Early Pain Benefit in Adhesive Capsulitis
Photo by CDC / Unsplash
Key Takeaway
Consider that SSNB may offer immediate pain relief but not a long-term functional benefit over IAS alone for adhesive capsulitis.

This randomized clinical trial enrolled 96 patients with adhesive capsulitis to compare three interventions: intra-articular steroid (IAS) injection plus suprascapular nerve block (SSNB), IAS injection alone, and physical therapy (PT) as a control. The primary outcome was improvement in Shoulder Pain and Disability Index (SPADI) scores at 12 weeks post-intervention, with secondary assessments including VAS pain, QuickDASH, Constant-Murley ROM, quality of life (QoL), and medication use (MQS 3) at day 0 and weeks 2, 6, and 12.

At week 2, the IAS+SSNB group showed a statistically significant improvement in SPADI scores over the IAS-only group (33.6±8.0 vs 38.3±8.9, p=0.04). A notable decrease in VAS pain was also observed in the immediate post-intervention period for the combination group. SPADI, VAS, QuickDASH, and Constant-Murley ROM scores showed significant reduction or improvement from baseline through week 12 in both the IAS and IAS+SSNB groups (p<0.05). MQS 3 scores decreased significantly up to week 6 in both groups. However, no significant changes in QoL were observed among the groups (p>0.05).

Critically, the study found no clinically significant difference in outcomes between the IAS+SSNB and IAS-only groups by week 12, except for the immediate VAS decrease. Safety and tolerability data, including adverse events and discontinuations, were not reported. Key limitations, such as sample size justification, blinding procedures, and specific PT protocol details, were not described in the provided data, which tempers the strength of the conclusions.

For practice, this evidence indicates that adding an SSNB to a standard IAS injection may provide a short-term analgesic advantage in the first few weeks, particularly for immediate post-procedure pain. However, it does not appear to confer a clinically meaningful benefit on the 12-week functional outcome trajectory for adhesive capsulitis. The absence of reported safety data necessitates caution.

Study Details

Study typeRct
EvidenceLevel 2
PublishedApr 2026
View Original Abstract ↓
BACKGROUND: Adhesive capsulitis is a distressing ailment that progressively limits the active and passive mobility of the shoulder joint. Physical therapy (PT) combined with intra-articular steroid (IAS) injection and suprascapular nerve block (SSNB) has shown improved functional outcomes. We aimed to assess whether providing both IAS injection and SSNB improved outcomes compared with IAS injection alone. METHODS: Ninety-six patients with adhesive capsulitis were randomized into three groups consisting of group IAS, group IAS+SSNB and group PT (control). All patients were assessed on day 0, week 2, 6 and 12 postintervention. The primary outcome was an improvement in Shoulder Pain and Disability Index (SPADI) scores at week 12 postintervention. Secondary outcomes were Visual Analog Scale (VAS), Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH) scores, Constant-Murley Range of Motion (ROM) scores, Quality of life (QoL) and Medication Quantification Scale (MQS) 3. RESULTS: On combining IAS and SSNB, we found a statistically significant improvement in SPADI scores over IAS only at week 2 postintervention (33.6±8.0 vs 38.3±8.9, p=0.04) but not beyond. A significant reduction in SPADI, VAS and QuickDASH scores, along with an improvement in Constant-Murley ROM scores, was observed on day 0 and at weeks 2, 6 and 12 in both group IAS and group IAS+SSNB (p<0.05). MQS 3 scores significantly decreased up to week 6 in both groups. However, the addition of SSNB to IAS did not demonstrate a clinically significant difference in the study outcomes, except for a notable decrease in VAS in the immediate postintervention period. Additionally, no significant changes in QoL were observed among the groups (p>0.05). CONCLUSION: Both IAS and IAS+SSNB improved analgesia, reduced disability and enhanced ROM. However, adding SSNB to IAS did not yield a clinically meaningful benefit in the study outcomes.Trial registration number TRIAL REGISTRATION NUMBER: CTRI/2022/08/044519.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.